AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...
GlobalData on MSN3d
AstraZeneca reports positive outcomes from trial of Imfinzi
AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...
Fierce Pharma6d
AstraZeneca touts disease recurrence win, ‘strong trend’ in survival benefit for Imfinzi in early stomach cancer
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
CURE5d
Imfinzi Plus Chemo May Improve Event-Free Survival in Gastric, GEJ Cancers
Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...
MedPage Today4h
NCI Flags 'Cancer Moonshot'; Dr. Hologram Will See You; Fraud Crackdown Continues
The American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...
BioSpace6d
AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
PMLive6d
AstraZeneca announces promising late-stage results for Imfinzi in gastric cancer
AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...
The Pharma Letter6d
Imfinzi combo shines in Phase III stomach cancer trial
A treatment combining AstraZeneca’s (LSE: AZN) immunotherapy Imfinzi (durvalumab) with chemotherapy has significantly reduced ...
CURE7d
How the FDA Approval of Imfinzi Advances Small Cell Lung Cancer Treatment
The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer ...
Benzinga.com6d
AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients
Imfinzi plus chemotherapy significantly improved event-free survival in resectable Stage II-IVA gastric and GEJ cancer patients. A strong trend in overall survival benefit was observed ...
PharmiWeb9d
Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable non-small cell lung cancer
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...